Balaji Amines (530999) May 2026 Filing Analysis

The Acetonitrile expansion is on track for FY2026-27. The plant is currently running at low utilization (5-10%) due to ongoing modification work using improved technology. (1 in progress across 1 tracked commitment)

Expansion project in subsidiary Balaji Speciality Chemicals Limited (BSCL) for EDA based products. — target: Additional reactor for DETA, TETA, PIP, AEEA, AEP etc. (+2 more commitments)

Strategic investment in products for EV battery industry. — target: Electronic Grade DMC, NMP, and TEA (+1 more commitment)

The company is expanding its backward integration by commissioning a new solar power plant to reduce utility costs and upgrading plants to consume low-cost internal products for high-value output. (4 expanding)

Amines volumes grew to 8,316 MT in Q4 FY25 from 7,746 MT in the prior year, showing steady demand from the pharmaceutical sector despite pricing pressures. (2 expanding, 1 contracting across 1 engine)

The Hotel Division's revenue share increased slightly to 2.56% of total revenue, up from 2.28%, with high occupancy rates of 71% providing stable cash flows. (3 expanding, 2 stable across 3 engines)

The company maintained its zero-debt status on a standalone basis while significantly increasing consolidated debt to fund massive expansions. (1 stable)

Specialty Chemicals volumes contracted slightly to 9,167 MT from 10,660 MT, reflecting a shift in product mix or demand fluctuations in end-user industries like agrochemicals. (1 contracting, 1 stable, 2 expanding)

The company is doubling its capacity for Acetonitrile using upgraded technology to improve cost efficiency and produce higher-quality grades for the pharma industry.

The subsidiary's expansion has been granted 'Mega Project' status by the Maharashtra government, involving a Rs. 750 crore investment. Environmental clearance has been cleared in the committee meeting, signaling steady progress toward import substitution. (3 steady, 1 new trend across 4 signals, 1 leading indicator)

The company successfully commissioned its new Methylamines plant on November 10, 2024, nearly doubling its capacity. This is a major milestone as 80% of this production is used internally for higher-value products, providing a cost advantage over competitors. (1 accelerating, 1 reversing, 1 new trend, 2 steady across 5 signals, 2 leading indicators)

The Electronic Grade DMC plant is nearing completion with most equipment received at the site. Commissioning is expected by March 2025, positioning the company as the only Indian manufacturer for this critical EV battery component. (1 accelerating, 4 new trend across 5 signals, 1 leading indicator)

The company maintains a strong global presence with 65+ international customers. However, export revenue as a percentage of total revenue for FY24 was 14.28%, which is relatively low compared to industry leaders. (5 steady across 5 signals, 1 leading indicator)

This risk remains stable as the pharmaceutical sector continues to provide the 'base volumes' and stable demand that offsets volatility in other segments like agrochemicals. (2 stable, 3 easing, 1 high-severity)

Execution risk is intensifying as Capital Work-in-Progress (CWIP) has increased from Rs. 150 Cr to Rs. 173 Cr at the standalone level, and the company has added a massive Rs. 750 Cr expansion plan for its subsidiary. (2 intensifying, 3 easing, 1 high-severity)

The risk is intensifying as management explicitly cites 'dumping from China' as a primary reason for the subsidiary's poor performance and the temporary closure of the Ethylenediamine (EDA) plant. (1 intensifying)

The risk is stable; management acknowledges that sourcing consistent supplies of raw materials like Methanol (primarily imported) remains key for the industry. (3 stable, 1 intensifying)

Export concentration remains a factor, but total export revenue as a percentage of total revenue is relatively low at 12.8%, providing a buffer against global shocks. (2 stable)